Brain+ CEO: CST is becoming the standard in dementia care [Video]

Brain+ is a health tech company focused on treatment and management of dementia. Centred around Cognitive Stimulation Therapy, the company’s approach has the potential to revolutionize dementia care. CEO Kim Baden-Kristensen stopped by the BioStock Studio to talk about Brain+’s path-to-market and the future of dementia management.

0:00 Intro
0:32 What is Brain+?
2:43 Why the UK?
4:19 Go-to-market strategy
5:59 Competitive landscape
7:16 How CST fits with pharmaceuticals
8:30 Market expansion plans
09:42 Future of dementia management
11:03 The right time to invest in Brain+

Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: https://www.linkedin.com/company/biostock
Facebook: https://www.facebook.com/biostock.se

https://www.biostock.se/
#BioStock #LifeScience #BrainPlus

About BioStock
BioStock is Scandinavia’s leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office and tv-studio is found at Medicon Village in Lund, one of Sweden’s foremost innovation clusters for life science companies

Disclaimer
BioStock is a news service and does not provide investment advice, does not convey investment orders and assumes no responsibility for actions and/or any loss or damage of any kind based on the use of content posted on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock’s news is independent, but as BioStock’s operations are partly financed by companies in the industry, BioStock’s website may contain news about companies from which BioStock has received financing.

This material has been created for marketing purposes and is not and should not be considered a prospectus under applicable laws and regulations. The complete terms and conditions for the rights issue and more information about the company have been presented in a prospectus published on the above-mentioned company’s website.